HomeREGULATORY
REGULATORY

MHLW Panel Backs Japan’s 1st PD-L1 Inhibitor, 8-Week Hep C Med and More
(Sep.11.2017)

A key advisory committee of the Ministry of Health, Labor and Welfare (MHLW) on September 8 recommended approval for a throng of new drugs including Merck Serono’s avelumab, which is now certain to be the 1st PD-L1 inhibitor in Japan, and AbbVie’s eight-week hepatitis C therapy glecaprevir/pibrentasvir (G/P) ...
(LOG IN FOR FULL STORY)

News Calendar